002382SZSE

Announcement on Seeking Shareholder Authorization for Board to Handle Private Placement of Shares via Simplified Procedures

✨ AI Summary

The company seeks shareholder approval to authorize the board of directors to conduct a private placement of shares via simplified procedures. The total funds raised will not exceed RMB 300 million, representing no more than 20% of net assets at the end of the previous year. The authorization period is from the 2025 to the 2026 annual shareholder meeting.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_documentSign In to Upgrade

Securities Code: 002382 Bond Code: 128108 Securities Abbreviation: Lanxess Medical Bond Abbreviation: Lanxess Convertible Bond Announcement Number: 2026-045

Lanxess Medical Co., Ltd. Announcement on Seeking Shareholder Authorization for Board to Handle Private Placement of Shares via Simplified Procedures

The Company and all members of the Board of Directors guarantee that the information disclosed is true, accurate, and complete, and contains no false records, misleading statements, or material omissions.

Lanxess Medical Co., Ltd. (hereinafter referred to as the "Company") held the 42nd meeting of the 6th Board of Directors on April 27, 2026, and reviewed and approved the "Proposal on Seeking Shareholder Authorization for the Board of Directors to Handle Private Placement of Shares via Simplified Procedures." In accordance with the "Administrative Measures for the Registration of Securities Issuances by Listed Companies" (hereinafter referred to as the "Registration Measures"), the "Shenzhen Stock Exchange Listing Review Rules for Securities Issuances and Listings," and the "Articles of Association of Lanxess Medical Co., Ltd." (hereinafter referred to as the "Articles of Association"), it is agreed to seek shareholder authorization for the Board of Directors to handle the private placement of shares via simplified procedures. The total funds raised will not exceed RMB 300 million and will not exceed 20% of the net assets at the end of the previous year. The authorization period is from the date of approval at the Company's 2025 annual shareholder meeting to the date of the Company's 2026 annual shareholder meeting. The details are as follows:

Sign in to read the full translation

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.